RT Journal Article
SR Electronic
T1 Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal protection against Omicron
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.12.22278720
DO 10.1101/2022.08.12.22278720
A1 Hao, Linhui
A1 Hsiang, Tien-Ying
A1 Dalmat, Ronit R.
A1 Ireton, Renee
A1 Morton, Jennifer
A1 Stokes, Caleb
A1 Netland, Jason
A1 Hale, Malika
A1 Thouvenel, Chris
A1 Wald, Anna
A1 Franko, Nicholas M
A1 Huden, Kristen
A1 Chu, Helen
A1 Greninger, Alex
A1 Tilles, Sasha
A1 Barrett, Lynn K.
A1 Van Voorhis, Wesley C.
A1 Munt, Jennifer
A1 Scobey, Trevor
A1 Baric, Ralph S.
A1 Rawlings, David
A1 Pepper, Marion
A1 Drain, Paul K.
A1 Gale, Michael
YR 2022
UL http://medrxiv.org/content/early/2022/08/16/2022.08.12.22278720.abstract
AB To evaluate SARS-CoV-2 variants we isolated SARS-CoV-2 temporally during the pandemic starting with first appearance of virus in the Western hemisphere near Seattle, WA, USA, and isolated each known major variant class, revealing the dynamics of emergence and complete take-over of all new cases by current Omicron variants. We assessed virus neutralization in a first-ever full comparison across variants and evaluated a novel monoclonal antibody (Mab). We found that convalescence greater than 5-months provides little-to-no protection against SARS-CoV-2 variants, vaccination enhances immunity against variants with the exception of Omicron BA.1, and paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50-fold enhanced protection against Omicron BA.1 compared to a 2-dose regimen. We also reveal a novel Mab that effectively neutralizes Omicron BA.1 and BA.2 variants over clinically-approved Mabs. Our observations underscore the need for continued vaccination efforts, with innovation for vaccine and Mab improvement, for protection against variants of SARS-CoV-2.Summary We isolated SARS-CoV-2 temporally starting with emergence of virus in the Western hemisphere. Neutralization analyses across all variant lineages show that vaccine-boost regimen provides protection against Omicron BA.1. We reveal a Mab that protects against Omicron BA.1 and BA.2 variants.Competing Interest StatementDr. Chu reported consulting with Ellume, Pfizer, The Bill and Melinda Gates Foundation, Vindico CME, and Merck. She has received research funding from Gates Ventures, Sanofi Pasteur, and support and reagents from Ellume and Cepheid outside of the submitted work. Dr. Pepper is a member of the scientific advisory board of VaxArt. Dr. Gale is a founding scientist of HDT Bio.Funding StatementSupported by NIH grant AI100625 (MG) and AI151698 (MG & WCVV, UWARN).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University of Washington gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript